Header Logo

BRIAN FRANCIS CHAPIN

TitleAssistant Professor
InstitutionMD Anderson
DepartmentUrology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Ch?ry L, Urkmez A, Fang AM, Higgason N, Troncoso P, Daniel CR, Logothetis C, Thompson TC, Hahn AW, Liu M, Zheng Y, Lin DW, Hanash S, Irajizad E, Fahrmann J. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res. 2024 Nov 09; 12(1):134. PMID: 39522029; PMCID: PMC11550521.
      Citations:    
    2. Fang AM, Gregg JR, Pettaway C, Ma J, Szklaruk J, Bathala TK, Surasi DSS, Chapin BF. Whole-body MRI for staging prostate cancer: a narrative review. BJU Int. 2024 Sep 22. PMID: 39308142.
      Citations:    Fields:    
    3. Fang AM, Chapin BF, Shi CW, Sun J, Qayyum A, Kundra V, Corn PG, Kuban DA, Ravizzini GC, Surasi DSS, Ma J, Bathala TK. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2024 Sep 17. PMID: 39289537.
      Citations:    Fields:    
    4. Kuo PH, Esposito G, Ulaner GA, Yoo D, Zukotynski K, Ravizzini GC, Penny R, Miller MP, Chau A, Davis P, Chapin BF, Schuster DM, SPOTLIGHT and LIGHTHOUSE study groups. Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies. J Nucl Med. 2024 Aug 01; 65(8):1239-1243. PMID: 38871390; PMCID: PMC11294070.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Sosa AJ, Rooney MK, Thames HD, Sanders JW, Swanson DM, Choi SL, Nguyen QN, Mok H, Kuban DA, Ron Zhu X, Shah S, Mayo LL, Hoffman KE, Tang C, McGuire SE, Sahoo N, Zhang X, Lee AK, Pugh TJ, Mahmood U, Davis JW, Chapin BF, Corn P, Kudchadker R, Ausat N, Frank SJ. Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822. PMID: 39188999; PMCID: PMC11345681.
      Citations:    
    6. Boesen L, Chapin BF. Re: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. Eur Urol. 2024 Nov; 86(5):479-480. PMID: 39043550.
      Citations:    Fields:    
    7. Fleming MT, Hermsen R, Purysko AS, Chau A, Davis P, Chapin BF, Schuster DM. True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med. 2024 Jul 01; 65(7):1080-1086. PMID: 38782456; PMCID: PMC11218719.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pili? PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458. PMID: 38837608.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Rais-Bahrami S, Bathala T, Chapin BF. Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 May; 25(5):617-618. PMID: 38642282.
      Citations:    Fields:    
    10. Lowentritt BH, Jani AB, Helfand BT, Uchio EM, Morris MA, Michalski JM, Chau A, Davis P, Chapin BF, Schuster DM, SPOTLIGHT Study Group. Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study. Adv Radiat Oncol. 2024 Aug; 9(8):101532. PMID: 39104875; PMCID: PMC11298587.
      Citations:    
    11. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). PMID: 38774466; PMCID: PMC11108024.
      Citations: 1     
    12. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). PMID: 38774467; PMCID: PMC11107999.
      Citations:    
    13. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr; 211(4):518-525. PMID: 38421243.
      Citations: 3     Fields:    Translation:Humans
    14. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr; 211(4):526-532. PMID: 38421252.
      Citations: 3     Fields:    Translation:Humans
    15. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024 Apr; 211(4):509-517. PMID: 38421253.
      Citations:    Fields:    Translation:Humans
    16. Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Ch?ry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol. 2024 04; 42(4):116.e1-116.e7. PMID: 38262868.
      Citations: 1     Fields:    Translation:Humans
    17. Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Bathala T, Chapin BF, Rais-Bahrami S. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 01; 25(1):66-83. PMID: 38212510.
      Citations:    Fields:    Translation:Humans
    18. Kiani K, Kim SP, Pessoa RR, Gershman B, Gonzalez C, Molina E, Warren A, DaSilva RD, Chapin B, Ballon-Landa E. Association of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort. Urol Pract. 2024 01; 11(1):117-122. PMID: 37914379.
      Citations:    Translation:Humans
    19. Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, Grand Challenge PRECISION Consortium, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell. 2023 08 31; 186(18):3968-3982.e15. PMID: 37586362.
      Citations: 2     Fields:    Translation:HumansCells
    20. Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM. Reply by Authors. J Urol. 2023 Aug; 210(2):310-311. PMID: 37416959.
      Citations: 1     Fields:    
    21. Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, LIGHTHOUSE Study Group. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. 2023 10; 84(4):361-370. PMID: 37414702.
      Citations: 6     Fields:    Translation:Humans
    22. Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Saltzstein D, Fleming MT, Chau A, Chapin BF, Schuster DM, Twardowski P, Davis P. Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply. J Urol. 2023 09; 210(3):411-412. PMID: 37350185.
      Citations: 3     Fields:    Translation:Humans
    23. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):825-834. PMID: 37022702; PMCID: PMC10080407.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    24. Andrews JR, Sood A, Chapin BF. Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer. J Urol. 2023 08; 210(2):242-243. PMID: 37194136.
      Citations:    Fields:    Translation:Humans
    25. Jani AB, Ravizzini GC, Fleming MT, Chau A, Chapin BF, Schuster DM, Siegel BA, Gartrell BA, Twardowski P, Saltzstein D, Davis P, SPOTLIGHT Study Group. Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023 08; 210(2):299-311. PMID: 37126069.
      Citations:    Fields:    Translation:Humans
    26. Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int. 2023 09; 132(3):307-313. PMID: 37057728.
      Citations:    Fields:    Translation:Humans
    27. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3). PMID: 36948506; PMCID: PMC10040066.
      Citations:    Fields:    Translation:HumansCells
    28. Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, Spratt DE, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NG. Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):919-935. PMID: 35840112.
      Citations:    Fields:    
    29. Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2022 03; 4(2):e210091. PMID: 35212559; PMCID: PMC8965534.
      Citations:    Fields:    Translation:Humans
    30. Ranasinghe WKB, Troncoso P, Surasi DS, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TK, Ibarra Rovira JJ. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology. 2022 04; 303(1):110-118. PMID: 35076303.
      Citations:    Fields:    Translation:Humans
    31. Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SE. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264. PMID: 34775795.
      Citations:    Fields:    Translation:HumansPHPublic Health
    32. Shapiro DD, Davis JW, Williams WH, Chapin BF, Ward JF, Pettaway CA, Gregg JR. Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. BJUI Compass. 2022 Jan; 3(1):68-74. PMID: 35475154; PMCID: PMC8988518.
      Citations: 2     
    33. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267. PMID: 34536949.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    34. Geskin AA, Westney OL, Graber WJ, Smith Iii TG, Chapin BF, Gregg JR. Complications Of Peri-Operative Ureteral Catheter Placement: Experience at A Major Cancer Center. Urology. 2022 06; 164:88-93. PMID: 34280440.
      Citations: 2     Fields:    Translation:Humans
    35. Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac H, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun. 2021 Jul 01; 42(7):755-762. PMID: 33741867.
      Citations:    Fields:    Translation:Humans
    36. McCormick BZ, Chery L, Chapin BF. Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. Transl Androl Urol. 2021 May; 10(5):2178-2187. PMID: 34159100; PMCID: PMC8185652.
      Citations:    
    37. Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SP. Research highlights of the 2020 society of urologic oncology young urologic oncologists' program. Urol Oncol. 2021 08; 39(8):452-454. PMID: 33858748; PMCID: PMC9647056.
      Citations:    Fields:    Translation:Humans
    38. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358. PMID: 33824525.
      Citations: 3     Fields:    Translation:Humans
    39. Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol. 2021 09; 80(3):389-390. PMID: 33824032.
      Citations:    Fields:    Translation:Humans
    40. Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer. 2021 05 01; 127(9):1425-1431. PMID: 33721334.
      Citations:    Fields:    Translation:Humans
    41. Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology. 2021 09; 155:144-151. PMID: 33676955.
      Citations:    Fields:    Translation:Humans
    42. Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. 2021 03 01; 127(5):720-728. PMID: 33411364; PMCID: PMC9810094.
      Citations: 3     Fields:    Translation:Humans
    43. Tang C, Lei X, Smith GL, Pan HY, Hoffman KE, Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BD. Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1286-1295. PMID: 33316361; PMCID: PMC8647931.
      Citations: 3     Fields:    Translation:Humans
    44. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306. PMID: 33279304.
      Citations: 4     Fields:    Translation:Humans
    45. Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, Chapin BF, Nyame YA. Surgical management of high-risk, localized prostate cancer. Nat Rev Urol. 2020 12; 17(12):679-690. PMID: 33173205.
      Citations: 4     Fields:    Translation:Humans
    46. Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? J Clin Oncol. 2021 01 01; 39(1):13-16. PMID: 33048621.
      Citations: 1     Fields:    Translation:Humans
    47. Westerman ME, Tabakin AL, Sexton WJ, Chapin BF, Singer EA. Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs. Urol Oncol. 2021 06; 39(6):357-364. PMID: 33160843; PMCID: PMC7524707.
      Citations: 2     Fields:    Translation:HumansCells
    48. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29. PMID: 32960678.
      Citations: 15     Fields:    Translation:Humans
    49. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21. PMID: 32960679.
      Citations: 34     Fields:    Translation:Humans
    50. Shapiro DD, Gregg JR, Lim AH, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF, Nogueras-Gonz?lez GM. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int. 2021 03; 127(3):340-348. PMID: 32357283; PMCID: PMC9798524.
      Citations: 4     Fields:    Translation:Humans
    51. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673. PMID: 32453443.
      Citations: 4     Fields:    Translation:Humans
    52. Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med. 2020 May; 45(5):349-355. PMID: 31977495.
      Citations:    Fields:    Translation:Humans
    53. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985. PMID: 32353391; PMCID: PMC10018317.
      Citations: 1     Fields:    Translation:Humans
    54. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292. PMID: 32298794; PMCID: PMC7395481.
      Citations: 2     Fields:    Translation:Humans
    55. Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. J Urol. 2020 10; 204(4):748-753. PMID: 32259468.
      Citations:    Fields:    Translation:Humans
    56. Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020 06; 125(6):792-800. PMID: 32176456.
      Citations: 10     Fields:    Translation:Humans
    57. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537). PMID: 32238575.
      Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
    58. Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020 06; 214(6):1248-1258. PMID: 32130049.
      Citations: 5     Fields:    Translation:Humans
    59. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255. PMID: 32191331; PMCID: PMC7082722.
      Citations: 8     Fields:    Translation:Humans
    60. Surasi DSS, Chapin B, Tang C, Ravizzini G, Bathala TK. Imaging and Management of Prostate Cancer. Semin Ultrasound CT MR. 2020 Apr; 41(2):207-221. PMID: 32446432.
      Citations: 2     Fields:    Translation:Humans
    61. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97. PMID: 31899230; PMCID: PMC7141963.
      Citations: 2     Fields:    Translation:Humans
    62. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514. PMID: 31742674; PMCID: PMC6980273.
      Citations: 7     Fields:    Translation:Humans
    63. Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178. PMID: 31501508; PMCID: PMC7027969.
      Citations:    Fields:    Translation:Humans
    64. Reichard CA, Chapin BF. Editorial Comment. Urology. 2019 09; 131:174. PMID: 31451157.
      Citations:    Fields:    Translation:Humans
    65. Ranasinghe WKB, Reichard CA, Bathala T, Chapin BF. Management of cT4 Prostate Cancer. Eur Urol Focus. 2020 03 15; 6(2):221-226. PMID: 31266732.
      Citations: 4     Fields:    Translation:Humans
    66. Ranasinghe WKB, Reichard CA, Chapin BF. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. Eur Urol. 2019 Nov; 76(5):543-545. PMID: 31248604; PMCID: PMC6922301.
      Citations:    Fields:    Translation:Humans
    67. Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819. PMID: 31009137.
      Citations: 11     Fields:    Translation:Humans
    68. Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. 2021 01; 7(1):71-77. PMID: 31076357.
      Citations:    Fields:    Translation:Humans
    69. Chapin BF. Clinical Trials in Urology. Urol Oncol. 2019 05; 37(5):303-304. PMID: 30904395.
      Citations:    Fields:    Translation:Humans
    70. Sundi D, Chapin BF. Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. Oncotarget. 2019 Mar 08; 10(20):1870-1871. PMID: 30956769; PMCID: PMC6443009.
      Citations:    Fields:    
    71. Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BF. Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome? BJU Int. 2019 08; 124(2):282-289. PMID: 30653804.
      Citations: 6     Fields:    Translation:Humans
    72. Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. J Urol. 2019 02; 201(2):308-314. PMID: 30179617; PMCID: PMC9798525.
      Citations: 2     Fields:    Translation:Humans
    73. Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CR. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer. 2019 02; 120(4):466-471. PMID: 30679782; PMCID: PMC6462004.
      Citations: 2     Fields:    Translation:Humans
    74. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264. PMID: 31200839.
      Citations: 2     Fields:    Translation:Humans
    75. Patel DN, Chapin BF, Freedland SJ. Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):1005. PMID: 30458585.
      Citations:    Fields:    Translation:Humans
    76. Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer. 2019 02 01; 125(3):391-397. PMID: 30423193.
      Citations: 12     Fields:    Translation:Humans
    77. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Chapin BF, Freedland SJ, Terris MK. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004. PMID: 30253446; PMCID: PMC6279517.
      Citations: 1     Fields:    Translation:Humans
    78. Jaber Y, Reichard CA, Chapin BF. Emerging role of cytoreductive prostatectomy in patients with metastatic disease. Transl Androl Urol. 2018 Sep; 7(Suppl 4):S505-S513. PMID: 30363448; PMCID: PMC6178312.
      Citations: 3     
    79. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532. PMID: 29988098.
      Citations: 13     Fields:    Translation:Humans
    80. Chapin BF, Cartapatti M, Machado RD, Muller RL, Magnabosco WJ, Santos AC, Melani A, Talvane A, Tobias-Machado M, Faria EF. Synchronous abdominal tumors: is combined laparoscopic surgery in a single approach a safe option? Int Braz J Urol. 2018 May-Jun; 44(3):483-490. PMID: 29219275; PMCID: PMC5996783.
      Citations: 3     Fields:    Translation:Humans
    81. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018 08; 74(2):140-143. PMID: 29656854.
      Citations: 5     Fields:    Translation:Humans
    82. Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 2018 07; 122(1):66-75. PMID: 29446205.
      Citations: 4     Fields:    Translation:Humans
    83. Reichard C, Chapin BF. Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy. Eur Urol Focus. 2017 12; 3(6):524-525. PMID: 29439879.
      Citations:    Fields:    Translation:Humans
    84. Kukreja JB, Thompson IM, Chapin BF. Organizing a clinical trial for the new investigator. Urol Oncol. 2019 05; 37(5):336-339. PMID: 29395953; PMCID: PMC6922302.
      Citations:    Fields:    Translation:Humans
    85. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis. 2018 06; 21(2):221-227. PMID: 29230008.
      Citations: 6     Fields:    Translation:Humans
    86. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018 04; 21(1):4-21. PMID: 29230009.
      Citations: 28     Fields:    Translation:Humans
    87. Chapin BF, Bellmunt J. 'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 11; 27(6):532. PMID: 28922341.
      Citations:    Fields:    Translation:Humans
    88. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548. PMID: 28941030.
      Citations: 8     Fields:    Translation:Humans
    89. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW. A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol. 2018 01; 36(1):13.e19-13.e25. PMID: 28964658.
      Citations: 2     Fields:    Translation:Humans
    90. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901; PMCID: PMC6126916.
      Citations: 6     Fields:    Translation:Humans
    91. Reichard CA, Chapin BF. Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders? Eur Urol. 2017 09; 72(3):352-353. PMID: 28552614.
      Citations:    Fields:    Translation:Humans
    92. Metcalfe MJ, Chapin BF. Editorial Comment. Urology. 2017 08; 106:151-152. PMID: 28550942.
      Citations:    Fields:    
    93. Williams SB, Huo J, Chapin BF, Smith BD, Hoffman KE. Impact of urologists' ownership of radiation equipment in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2017 09; 20(3):300-304. PMID: 28349981; PMCID: PMC9846832.
      Citations:    
    94. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 04; 35(4):125-134. PMID: 28190749.
      Citations: 7     Fields:    Translation:Humans
    95. Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer. 2017 05 01; 123(9):1617-1624. PMID: 28099688; PMCID: PMC5897905.
      Citations: 9     Fields:    Translation:Humans
    96. Williams SB, Chapin BF. Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom? Eur Urol. 2017 05; 71(5):738-739. PMID: 27815080.
      Citations:    Fields:    Translation:Humans
    97. Bayne CE, Williams -B, Chapin BF. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87. Eur Urol. 2017 02; 71(2):e51. PMID: 27461403.
      Citations: 1     Fields:    Translation:Humans
    98. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42. PMID: 27325855.
      Citations: 68     Fields:    Translation:Humans
    99. Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016 Mar; 12(5):687-99. PMID: 26839141.
      Citations: 3     Fields:    Translation:Humans
    100. Chapin BF. Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy. Asian J Androl. 2015 Nov-Dec; 17(6):888-91. PMID: 26178396; PMCID: PMC4814949.
      Citations: 1     Fields:    Translation:Humans
    101. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8. PMID: 26558524.
      Citations: 4     Fields:    Translation:Humans
    102. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275; PMCID: PMC4808616.
      Citations: 17     Fields:    Translation:Humans
    103. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology. 2015 Jul; 86(1):10-5. PMID: 26048432.
      Citations: 14     Fields:    Translation:Humans
    104. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2016 05; 69(5):775-87. PMID: 26003223.
      Citations: 16     Fields:    Translation:Humans
    105. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol. 2014 Jun; 65(6):1067-8. PMID: 24411278.
      Citations: 2     Fields:    Translation:Humans
    106. Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu CL, Dahl DM. Midterm oncological outcomes of laparoscopic vs open radical prostatectomy (RP). BJU Int. 2013 Jul; 112(2):190-7. PMID: 23601185.
      Citations:    Fields:    Translation:Humans
    107. Delacroix SE, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. Urol Clin North Am. 2011 Nov; 38(4):419-28, vi. PMID: 22045173.
      Citations: 3     Fields:    Translation:Humans
    108. Delacroix SE, Chapin BF, Chen JJ, Nogueras-Gonzalez GM, Tamboli P, Matin SF, Wood CG. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol. 2011 Oct; 186(4):1236-41. PMID: 21849197.
      Citations: 16     Fields:    Translation:Humans
    109. Chapin BF, Delacroix SE, Wood CG. Renal cell carcinoma: what the surgeon and treating physician need to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1255-62. PMID: 21606286.
      Citations: 2     Fields:    Translation:Humans
    110. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71. PMID: 21621907; PMCID: PMC4378825.
      Citations: 29     Fields:    Translation:Humans
    111. Chapin BF, Delacroix SE, Wood CG. The role of lymph node dissection in renal cell carcinoma. Int J Clin Oncol. 2011 Jun; 16(3):186-94. PMID: 21523561.
      Citations:    Fields:    Translation:Humans
    112. Chapin BF, Wood CG. The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant? Eur Urol. 2011 Aug; 60(2):249-51; discussion 251-2. PMID: 21514040.
      Citations: 5     Fields:    Translation:Humans
    113. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8. PMID: 21367518.
      Citations: 66     Fields:    Translation:Humans
    114. Eisner BH, Feldman AS, Chapin BF, Dretler SP. "Blind coning"--using the Stone Cone for removal of intramural ureteral calculi. Urology. 2007 Apr; 69(4):773-5. PMID: 17445670.
      Citations:    Fields:    Translation:Humans
    115. Oyelese Y, Tchabo JG, Chapin B, Nair A, Hanson P, McLaren R. Conservative management of uterine rupture diagnosed prenatally on the basis of sonography. J Ultrasound Med. 2003 Sep; 22(9):977-80. PMID: 14510271.
      Citations: 3     Fields:    Translation:Humans
    116. Cytoreductive nephrectomy. 109-122.
    117. Patterns of Care for Prostate Cancer Patients. European Urology.
    118. Optimal management of prostate cancer with lethal biology - State-of-the-art local therapy. Asian Journal of Andrology. 17:888-891.
    119. Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology.
    120. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncology. 12:687-699.
    121. Reply to Lu Yang, Shi Qiu and Qiang Wei Letter to the Editor re. European Urology. 71:e51.
    122. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. Journal of Clinical Oncology. 34:2835-2842.
    123. Neoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity. Clinical Genitourinary Cancer. 14:130-138.
    CHAPIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (247)
    Explore
    _
    Co-Authors (72)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _